Motesanib | 莫特塞尼 | AMG 706 | c-Kit Inhibitor | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / / Motesanib/莫替沙尼

Motesanib/莫替沙尼 {[allProObj[0].p_purity_real_show]}

货号：A123381 同义名： 莫特塞尼 / AMG 706

Motesanib is an ATP-competitive inhibitor of VEGFR1 (IC50 = 2 nM), VEGFR2 (IC50 = 3 nM), VEGFR3 (IC50 = 6 nM) and Kit.

Motesanib/莫替沙尼化学结构
CAS号：453562-69-1

Motesanib/莫替沙尼 3D分子结构
CAS号：453562-69-1

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Motesanib/莫替沙尼纯度/质量文件产品仅供科研

货号：A123381 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: 更多 >

c-Kit 亚型比较
VEGFR 亚型比较

产品名称	c-Kit ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ c-Kit (Swiss 3T3), IC50: 1.8 μM	PDGFR	99%+
Masitinib	+ Kit, IC50: 200 nM		99%+
Motesanib Diphosphate	+++ Kit, IC50: 8 nM		99% (HPLC)
Ki8751	++ c-Kit, IC50: 40 nM		99%
Tivozanib	++ c-Kit, IC50: 78 nM		99%+
Pazopanib	+ c-Kit, IC50: 140 nM		99%
Sitravatinib	+++ Kit, IC50: 6 nM		99%+
Pexidartinib	+++ Kit, IC50: 10 nM		99%+
Lactate	++++ c-Kit, IC50: 2 nM	FLT3	85%
Amuvatinib	+++ c-Kit (D816H), IC50: 10 nM		99%+
Imatinib Mesylate	+ c-Kit, IC50: 100 nM	PDGFR	99%
AZD2932	+++ c-Kit, IC50: 9 nM		99%
Axitinib	++++ Kit, IC50: 1.7 nM		98%
Dovitinib	++++ c-Kit, IC50: 2 nM	FLT3	99%+
Sunitinib	✔	FLT3	98%
OSI-930	+ Kit, IC50: 80 nM		99%+
Telatinib	++++ c-Kit, IC50: 1 nM		99%+
Dasatinib monohydrate	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
Dasatinib	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	99% (HPLC)
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ VEGFR2, IC50: 25 nM Flk1, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,PDGFR,c-Kit	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Fms,c-Kit	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ hVEGFR2, IC50: 9 nM mVEGF2, IC50: 165 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Motesanib/莫替沙尼生物活性

描述	Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively, showing similar activity against Kit and being ~10-fold selective for VEGFR than PDGFR and Ret.

Motesanib/莫替沙尼临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00861419	Advanced Solid Tumors	Phase 1	Completed	-	-
NCT02084732	Thyroid Cancer	Phase 2	Unknown	June 2018	Colombia ... 展开 >> Instituto Nacional de Cancerología Recruiting Bogotá, Cundinamarca, Colombia, 00000 Contact: Yeinnyer C. Muleth, BSc 3340106 ymuleth@cancer.gov.co Principal Investigator: Luis F Fierro, Md Sub-Investigator: Gloria Garavito, Md Sub-Investigator: Andres A Cuellar, Md Sub-Investigator: Jose A. Carreño, Md Sub-Investigator: Juan S Castillo, Md 收起 <<
NCT01700699	-		Unknown	October 2013	Italy ... 展开 >> Department of Medicine and Surgery, Univeristy of Salerno Recruiting Baronissi, Salerno, Italy, 84081 Contact: Mario Vitale, MD +39 089672539 mavitale@unisa.it Principal Investigator: Mario Vitale, MD 收起 <<

Motesanib/莫替沙尼参考文献

[1]Kruser TJ, Wheeler DL, et al. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res. 2010 Jul 15;16(14):3639-47.

[2]Polverino A, Coxon A, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006 Sep 1;66(17):8715-21.

Motesanib/莫替沙尼实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.68mL

0.54mL

0.27mL

13.39mL

2.68mL

1.34mL

26.78mL

5.36mL

2.68mL

Motesanib/莫替沙尼技术信息

CAS号	453562-69-1
分子式	C₂₂H₂₃N₅O
分子量	373.45
SMILES Code	O=C(NC1=CC2=C(C=C1)C(C)(C)CN2)C3=C(NCC4=CC=NC=C4)N=CC=C3
MDL No.	MFCD10567689

别名	莫特塞尼 ;AMG 706
运输	蓝冰
InChI Key	RAHBGWKEPAQNFF-UHFFFAOYSA-N
Pubchem ID	11667893

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C

溶解方案

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00861419	Advanced Solid Tumors	Phase 1	Completed	-	-
NCT02084732	Thyroid Cancer	Phase 2	Unknown	June 2018	Colombia ... 展开 >> Instituto Nacional de Cancerología Recruiting Bogotá, Cundinamarca, Colombia, 00000 Contact: Yeinnyer C. Muleth, BSc 3340106 ymuleth@cancer.gov.co Principal Investigator: Luis F Fierro, Md Sub-Investigator: Gloria Garavito, Md Sub-Investigator: Andres A Cuellar, Md Sub-Investigator: Jose A. Carreño, Md Sub-Investigator: Juan S Castillo, Md 收起 <<
NCT01700699	-		Unknown	October 2013	Italy ... 展开 >> Department of Medicine and Surgery, Univeristy of Salerno Recruiting Baronissi, Salerno, Italy, 84081 Contact: Mario Vitale, MD +39 089672539 mavitale@unisa.it Principal Investigator: Mario Vitale, MD 收起 <<
NCT00324597	Lung Cancer L... 展开 >>ymphoma Lymphoproliferative Disorder Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Unknown	-	United States, California ... 展开 >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 收起 <<
NCT01265927	Breast Neoplasms	Phase 1	Completed	-	United States, Indiana ... 展开 >> Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT00310895	Solid Tumor Malignancies	Phase 1	Completed	-	United States, Illinois ... 展开 >> The University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Michigan Wayne State University, Karmanos Cancer Center Detroit, Michigan, United States, 48201 收起 <<
NCT00510445	Lung Cancer	Phase 1	Completed	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Texas The University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 UT MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 收起 <<
NCT00594126	Multiple Myeloma	Phase 1	Completed	-	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore, Maryland, United States, 21231 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT00718601	Multiple Myeloma	Phase 1	Completed	-	United States, Michigan ... 展开 >> Karmanos Cancer Center Detroit, Michigan, United States, 48201 United States, New York St. Vincent's Comprehensive Cancer Center New York City, New York, United States, 10011 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 收起 <<
NCT00356681	Breast Neoplasms ... 展开 >> Breast Tumors Breast Cancer Locally Recurrent and Metastatic Breast Cancer 收起 <<	Phase 2	Terminated(Sponsor decision to... 展开 >> close study) 收起 <<	-	-
NCT00369070	Advanced Non-squamous NSCLC	Phase 2	Terminated	-	-
NCT00427349	Gastrointestinal Carcinoid Tum... 展开 >>or Islet Cell Tumor Neoplastic Syndrome 收起 <<	Phase 2	Completed	-	-
NCT00360867	Solid Tumors	Phase 2	Terminated(Amgen decision)	-	-
NCT00427349	-		Completed	-	-
NCT00574951	Fallopian Tube Cancer ... 展开 >> Ovarian Cancer Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Terminated(Study was stopped f... 展开 >>or severe toxicity causing concern for patients) 收起 <<	-	United States, California ... 展开 >> Providence Saint Joseph Medical Center - Burbank Burbank, California, United States, 91505 United States, Connecticut George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus New Britain, Connecticut, United States, 06050 United States, Illinois University of Illinois Cancer Center Chicago, Illinois, United States, 60612-7243 Rush University Medical Center Chicago, Illinois, United States, 60612 Hinsdale Hematology Oncology Associates Hinsdale, Illinois, United States, 60521 United States, Indiana St. Vincent Indianapolis Hospital Indianapolis, Indiana, United States, 46260 United States, Missouri St. John's Regional Health Center Springfield, Missouri, United States, 65804 Hulston Cancer Center at Cox Medical Center South Springfield, Missouri, United States, 65807 United States, New Jersey Cancer Institute of New Jersey at Cooper - Voorhees Voorhees, New Jersey, United States, 08043 United States, North Carolina Blumenthal Cancer Center at Carolinas Medical Center Charlotte, North Carolina, United States, 28232-2861 United States, Ohio Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 Mount Carmel Health - West Hospital Columbus, Ohio, United States, 43222 Lake/University Ireland Cancer Center Mentor, Ohio, United States, 44060 United States, Oklahoma Oklahoma University Cancer Institute Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Rosenfeld Cancer Center at Abington Memorial Hospital Abington, Pennsylvania, United States, 19001 Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania, United States, 19111-2497 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center Reading, Pennsylvania, United States, 19612-6052 United States, Texas Harrington Cancer Center Amarillo, Texas, United States, 79106 United States, Virginia University of Virginia Cancer Center Charlottesville, Virginia, United States, 22908 收起 <<
NCT00574951	-		Terminated(Study was stopped f... 展开 >>or severe toxicity causing concern for patients) 收起 <<	-	-
NCT01386866	Advanced Solid Tumors	Phase 1	Completed	-	-
NCT01273090	Brain and Central Nervous Syst... 展开 >>em Tumors Lymphoma Lymphoproliferative Disorder Small Intestine Cancer Unspecified Childhood Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	-
NCT00094835	Lung Cancer N... 展开 >>on-Small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Completed	-	-
NCT01256762	Locally Recurrent or Metastati... 展开 >>c Breast Cancer 收起 <<	Phase 2	Completed	-	-
NCT00094835	-		Completed	-	-
NCT00460317	Non-Small Cell Lung Cancer	Phase 3	Terminated(Amgen discontinued ... 展开 >>the development of AMG706 because 20050201 did not meet its primary objective.) 收起 <<	-	-
NCT01568632	Solid Tumors ... 展开 >>Lymphoma 收起 <<	Phase 1	Withdrawn	-	-
NCT01137968	Non-small Cell Lung Cancer	Phase 2	Completed	-	-
NCT01731951	Primary Myelofibrosis ... 展开 >> Secondary Myelofibrosis Myeloid Malignancies 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Rochester, Minnesota, United States 收起 <<
NCT01243073	Essential Thrombocythemia ... 展开 >> Polycythemia Vera 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 United States, Florida MDACC - Orlando Orlando, Florida, United States, 32806 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland Johns Hopkins University - Bunting Blaustein Cancer Research Building Baltimore, Maryland, United States, 21205 United States, South Carolina Saint Francis Hospital Greenville, South Carolina, United States, 29601 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Germany University Hospital of Essen - West German Cancer Center Essen, Germany Medizinische Klinik II, Abt. Hämatologie und Onkologie - Johann Wolfgang Goethe Universität Frankfurt, Germany, D-60590 SLK-Kliniken GmbH Heilbronn, Germany Hematology Oncology Center - Ludwig-Maximilians, University Munich Medical School Munich, Germany, 80331 University Hospital Regensburg - Uniklinik Regensburg Regensburg, Germany Switzerland INSELSPITAL, University Hospital Bern Bern, Switzerland, CH - 3010 收起 <<
NCT02011126	Hepatoblastoma ... 展开 >> Previously Treated Childhood Rhabdomyosarcoma Recurrent Childhood Liver Cancer Recurrent Childhood Rhabdomyosarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent Osteosarcoma Rhabdomyosarcoma 收起 <<	Phase 2	Withdrawn(IND no longer availa... 展开 >>ble.) 收起 <<	-	-
NCT02629848	Carcinoma, Non-Small-Cell Lung	Phase 3	Terminated(Sponsor decision to... 展开 >> terminate the study because the study did not meet the primary endpoint.) 收起 <<	-	-
NCT01242930	Multiple Myeloma	Phase 2	Completed	-	United States, Maryland ... 展开 >> University of Maryland Medical Center - M & S Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Sidney Kimmel Cancer Center Johns Hopkins Hospital Baltimore, Maryland, United States, 21231 收起 <<
NCT02598661	Myelodysplastic Syndromes	Phase 3	Recruiting	February 28, 2022	-
NCT02426086	Primary Myelofibrosis	Phase 2	Active, not recruiting	April 26, 2019	-
NCT01836549	Anaplastic Astrocytoma ... 展开 >> Anaplastic Ependymoma Astrocytoma, Grade II Ependymoma Giant Cell Glioblastoma Glioblastoma Gliosarcoma Oligodendroglioma Brainstem Tumors 收起 <<	Phase 2	Terminated(Due to several intr... 展开 >>acranial hemorrhages and recommendation by the PBTC DSMB.) 收起 <<	-	United States, California ... 展开 >> Childrens Hospital Los Angeles Los Angeles, California, United States, 90027-0700 Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States, 94304 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010-2970 United States, Illinois Lurie Children's Hospital- Chicago Chicago, Illinois, United States, 60614 United States, Maryland NCI - Pediatric Oncology Branch Bethesda, Maryland, United States, 20892 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Saint Jude Children's Research Hospital Memphis, Tennessee, United States, 38105-2794 United States, Texas Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital Houston, Texas, United States, 77030-2399 收起 <<
NCT01836549	-		Terminated(Due to several intr... 展开 >>acranial hemorrhages and recommendation by the PBTC DSMB.) 收起 <<	-	-
NCT01916187	Neuroblastoma	Phase 1	Withdrawn(drug company withdrw... 展开 >>w support following a re-examination of the benefit-risk assessment for the investigational use of imetelstat in this population) 收起 <<	-	Canada, Quebec ... 展开 >> CHU Sainte-Justine Montreal, Quebec, Canada, H3T 1C5 收起 <<
NCT01349088	Breast Cancer ... 展开 >> Metastatic Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 1 Phase 2	Withdrawn	September 2018	United States, Pennsylvania ... 展开 >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 收起 <<

Motesanib/莫替沙尼 {[allProObj[0].p_purity_real_show]}

Motesanib/莫替沙尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Motesanib/莫替沙尼质控信息

Motesanib/莫替沙尼生物活性

Motesanib/莫替沙尼临床研究

Motesanib/莫替沙尼参考文献

Motesanib/莫替沙尼实验方案

Motesanib/莫替沙尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Motesanib/莫替沙尼 {[allProObj[0].p_purity_real_show]}

Motesanib/莫替沙尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Motesanib/莫替沙尼 质控信息

Motesanib/莫替沙尼 生物活性

Motesanib/莫替沙尼 临床研究

Motesanib/莫替沙尼 参考文献

Motesanib/莫替沙尼 实验方案

Motesanib/莫替沙尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Motesanib/莫替沙尼纯度/质量文件产品仅供科研

Motesanib/莫替沙尼质控信息

Motesanib/莫替沙尼生物活性

Motesanib/莫替沙尼临床研究

Motesanib/莫替沙尼参考文献

Motesanib/莫替沙尼实验方案

Motesanib/莫替沙尼技术信息